Gantenerumab
Gantenerumab
Gantenerumab (pronounced gan-te-ne-ru-mab) is a fully human anti-amyloid beta monoclonal antibody that is being investigated for the treatment of Alzheimer's disease.
Etymology
The name "Gantenerumab" is derived from the company that developed it, F. Hoffmann-La Roche AG, and the suffix "-mab" is an abbreviation for "monoclonal antibody".
Mechanism of Action
Gantenerumab works by binding to amyloid beta, a protein that accumulates in the brains of people with Alzheimer's disease. This binding triggers the body's immune system to remove the amyloid beta, potentially slowing the progression of the disease.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of Gantenerumab in patients with Alzheimer's disease. These include the SCarlet RoAD and Marguerite RoAD studies.
Related Terms
External links
- Medical encyclopedia article on Gantenerumab
- Wikipedia's article - Gantenerumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski